Dec 4, 2008 - Genta Incorporated announced today that the Company has received notice from the U.S. FDA that tesetaxel, the Company's oral taxane in clinical development, has been granted designation as an “Orphan Drug” for treatment of patients with advanced melanoma.
The details can be read here.
No comments:
Post a Comment